$82.19
0.02[0.02%]
At close: Apr 25
$82.19
0[0.00%]
PreMarket: 4:49PM EDT
Biomarin Pharmaceutical
(NASDAQ:BMRN)Biomarin Pharmaceutical Stock (NASDAQ:BMRN), Analyst Ratings, Price Targets, Predictions
Biomarin Pharmaceutical Inc has a consensus price target of $96.3, established from looking at the 87 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Scotiabank, and Cantor Fitzgerald on April 25, 2024. With an average price target of $95.33 between Citigroup, Scotiabank, and Cantor Fitzgerald, there's an implied 15.99% upside for Biomarin Pharmaceutical Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Scotiabank
Cantor Fitzgerald
Wells Fargo
Canaccord Genuity
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Biomarin Pharmaceutical
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/25/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 10.72% | Citigroup | David Lebovitz | $94 → $91 | Maintains | Neutral | Get Alert |
| 04/25/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 3.42% | Scotiabank | George Farmer | $83 → $85 | Maintains | Sector Perform | Get Alert |
| 04/25/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 33.84% | Cantor Fitzgerald | Olivia Brayer | → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 04/25/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 33.84% | Wells Fargo | Mohit Bansal | $100 → $110 | Maintains | Overweight | Get Alert |
| 02/29/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 10.72% | Canaccord Genuity | Whitney Ijem | → $91 | Reiterates | Hold → Hold | Get Alert |
| 02/23/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 30.19% | Piper Sandler | Christopher Raymond | $115 → $107 | Maintains | Overweight | Get Alert |
| 02/23/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 21.67% | Cantor Fitzgerald | Olivia Brayer | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 21.67% | RBC Capital | Luca Issi | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/30/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 26.54% | Baird | Joel Beatty | $127 → $104 | Maintains | Outperform | Get Alert |
| 12/21/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 22.89% | Stifel | Paul Matteis | → $101 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 21.67% | RBC Capital | Luca Issi | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/03/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 21.67% | BMO Capital | Kostas Biliouris | $102 → $100 | Maintains | Outperform | Get Alert |
| 11/02/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 39.92% | Piper Sandler | Christopher Raymond | $125 → $115 | Maintains | Overweight | Get Alert |
| 11/02/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 42.35% | Morgan Stanley | Matthew Harrison | $125 → $117 | Maintains | Overweight | Get Alert |
| 11/02/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 35.05% | Barclays | Gena Wang | $125 → $111 | Maintains | Overweight | Get Alert |
| 11/02/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 21.67% | Cantor Fitzgerald | Olivia Brayer | $120 → $100 | Maintains | Overweight | Get Alert |
| 10/23/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | -0.23% | Bernstein | William Pickering | → $82 | Upgrade | Underperform → Market Perform | Get Alert |
| 10/16/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | 46% | Cantor Fitzgerald | Olivia Brayer | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/28/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.19 | — | Raymond James | Laura Chico | — | Initiates | → Market Perform | Get Alert |
FAQ
What is the target price for Biomarin Pharmaceutical (BMRN)?
The latest price target for Biomarin Pharmaceutical (NASDAQ: BMRN) was reported by Citigroup on April 25, 2024. The analyst firm set a price target for $91.00 expecting BMRN to rise to within 12 months (a possible 10.72% upside). 47 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biomarin Pharmaceutical (BMRN)?
The latest analyst rating for Biomarin Pharmaceutical (NASDAQ: BMRN) was provided by Citigroup, and Biomarin Pharmaceutical maintained their neutral rating.
When was the last upgrade for Biomarin Pharmaceutical (BMRN)?
The last upgrade for Biomarin Pharmaceutical Inc happened on October 23, 2023 when Bernstein raised their price target to $82. Bernstein previously had an underperform for Biomarin Pharmaceutical Inc.
When was the last downgrade for Biomarin Pharmaceutical (BMRN)?
The last downgrade for Biomarin Pharmaceutical Inc happened on February 22, 2023 when Oppenheimer changed their price target from N/A to N/A for Biomarin Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Biomarin Pharmaceutical (BMRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
Is the Analyst Rating Biomarin Pharmaceutical (BMRN) correct?
While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a maintained with a price target of $94.00 to $91.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $82.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.